New MASTR Facility supports adoption of NGS

New MASTR Facility supports adoption of NGS

Molecular Diagnostics

September 15, 2015

Multiplicom is pleased to announce the new MASTR Facility to enable the implementation of massively parallel sequencing (MPS also referred to as NGS) capabilities in clinical genetics and pathology laboratories.

The genomic revolution and the rapid evolution of sequencing technologies present many exciting opportunities, as well as many challenges. The MASTR Facility can support you in dealing with these challenges in non-invasive prenatal testing, cancer predisposition screening, tumor analysis, and identification of genetic predisposition in areas such as cardiovascular disease. Multiplicom offers support for all our commercial assays through training, wet lab testing, as well as data analysis so you can reduce initial set-up costs and accelerate the adoption of NGS in your offering.

The combined offering of innovative diagnostic kits that enable clinical laboratories to link genetic information to health and disease and the actual performance of these tests empower lab clients to better serve the needs of physicians and their patients.

Identify new markers for cancer with qPCR

Identify new markers for cancer with qPCR

Molecular Diagnostics

One of the most exciting potential applications of circulating non-coding RNAs like microRNA (miRNA) and long non-coding RNA (lncRNA) is as biomarkers for early detection of cancer. Easily accessible markers like RNAs in the blood are an attractive possibility for finding cancers as soon as possible. Our scientists have compiled an application note showing how to use qPCR in translational research to identify potential lncRNA biomarkers in lung cancer. Check it out here!



December 20, 2016 More +
RIDAQUICK Gliadin - approved by AOAC

RIDAQUICK Gliadin - approved by AOAC

Molecular Diagnostics

R-biopharm is proud to announce that lateral flow test for gluten analysis is now approved by one of the most important organizations for method validation. The dip stick RIDA®QUICK Gliadin was approved by the AOAC Performance Tested Methods (SM) Program and was assigned PTM Certification No. 101702 by the AOAC Research Institute.

November 09, 2017 More +
Ready to make an enquiry Call us on: + 961 1 39 66 77
Or email us